Otonomy - OTIC Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings or view top-rated stocks.

3 analysts have issued 1-year target prices for Otonomy's stock. Their OTIC share price forecasts range from $0.50 to $6.00. On average, they anticipate the company's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 2,776.1% from the stock's current price.
View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts.

Otonomy's stock was trading at $0.0871 at the beginning of 2023. Since then, OTIC stock has increased by 29.7% and is now trading at $0.1130.
View the best growth stocks for 2023 here.

Otonomy, Inc. (NASDAQ:OTIC) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). During the same period in the previous year, the firm earned ($0.22) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OTIC stock can currently be purchased for approximately $0.11.

Otonomy (NASDAQ:OTIC) has a market capitalization of $7.74 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.